Showing results (321-330 of 403) with videos related to

Sort By:
Pageof 41
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 16, 2025
Non-cisplatin concurrent agents plus definitive radiotherapy for locally advanced head and neck cancer: A network meta-analysis of randomized studiesFausto Petrelli, Francesca Trevisan, Massimiliano Nardone, et al.
Critical Reviews in Oncology/Hematology|March 21, 2007
Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panelCesare Gridelli, Matti S Aapro, Sandro Barni, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 11, 2024
BRAF mutations and survival with surgery for colorectal liver metastases: A systematic review and meta-analysisFausto Petrelli, Marcella Arru, Silvia Colombo, et al.
Neoplasia (New York, N.Y.)|May 31, 2022
Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis: HCC and Steatosis or SteatohepatitisFausto Petrelli, Michele Manara, Silvia Colombo, et al.
Panminerva Medica|February 2, 2021
The core components of cardio-oncology rehabilitationElio Venturini, Susan Gilchrist, Elisabetta Corsi, et al.
Expert Opinion on Biological Therapy|February 4, 2020
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving NivolumabFrancesco Pantano, Marco Russano, Alfredo Berruti, et al.
The Lancet. Oncology|September 4, 2009
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind studyGiancarlo Agnelli, Gualberto Gussoni, Carlo Bianchini, et al.
The Oncologist|August 14, 2013
Dose-dense FEC followed by dose-dense ixabepilone as neoadjuvant treatment for breast cancer patients: a feasibility studyMatteo Clavarezza, Roberto Bordonaro, Bruno Daniele, et al.
Critical Reviews in Oncology/Hematology|July 13, 2026
Immune-Related Adverse Events From Checkpoint Inhibitors: An Evidence-Based Management ReviewFausto Petrelli, Lorenzo Dottorini, Mauro Rossitto, et al.
Clinical Colorectal Cancer|April 12, 2015
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II StudyNicola Personeni, Lorenza Rimassa, Claudio Verusio, et al.
Pageof 41